n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
Samsung Ventures Invests in Preclinical Biopharmaceutical Company BrickBio
The proceeds will be used for the progression and advancement of BrickBio’s protein engineering generation and preclinical assets.
INCHEON, Korea and WALTHAM, Mass. , March 18, 2024 /PRNewswire/ — Samsung Life Science Fund, jointly established through Samsung Biologics (KRX: 207940. KS), Samsung Bioepis and Samsung C
This new investment reflects Samsung’s commitment to finding and exploring new opportunities in the biopharmaceutical sector to address unmet healing needs. Samsung’s subsidiaries will work with BrickBio to evaluate, manufacture and expand complex molecules and treatments. BrickBio’s proprietary protein engineering generation for antibody-drug conjugates. (ADC), AAV gene therapy, and other modalities. The BrickBio generation uses an extensive genetic code to incorporate artificial amino acids into proteins, all terminated in a living cell. These artificial amino acids enable the creation of precision biologicals, an exciting new elegance of healing. with wide application and potential.
“We’re thrilled to get this from Samsung, as well as the popularity of the prospect of our complex generation of protein engineering to provide new answers to challenging medical conditions,” said John Boyce, CEO and co-founder of BrickBio and Gene Tiger. We look forward to using those benefits to continue our efforts to advance our ADC applicants to the clinic. “
“BrickBio’s extensive and physically powerful genetic code in mammalian cells provides the possibility to create molecules and treatments to address unmet needs,” said Ho Sung Cho, executive vice president and head of early research and development at Samsung Bioepis.
BrickBio’s innovation engine continues to expand the preclinical portfolio by finding valuable new systems that take full advantage of its technologies. These new systems have the potential to treat a wide variety of diseases with new or advanced mechanisms of action, offering the company a set of systems to expand internally and/or in partnership with leading pharmaceutical companies.
About BrickBio, Inc. BrickBio Inc. , a Boston-based biogeneration company, enables the conjugation of proteins along with next-generation unnatural amino acids through its selective, site-specific platform. The generation platform covers prokaryotic and eukaryotic expression systems. , enabling the progression of exclusive protein biologics and cures with enhanced characteristics, adding innovations in half-life, dosage, and efficacy. With the broadest toolbox of bioconjugation handles, BrickBio can optimize any conjugate and is uniquely positioned to overcome biologics barriers by selectively modifying different sites in a single protein. BrickBio is expanding its healing programs, adding ADCs, bispecific conjugates, and new scaffolds.
For more information, visit www. brickbio. com.
Corporate Contact:John BoyceDirector généraljohn. boyce@tigergenellc. com www. brickbio. com
About Samsung Ventures Samsung Venture Investment Corporation was created to advertise promising small and medium-sized enterprises involved in the advancement of new technologies. Our collaboration is based on management’s knowledge and trust, and on active investment in forward-thinking companies, founded on new and cutting-edge technologies that serve as new drivers of expansion. Visit our online page for more details; https://www. samsungventure. co. kr/english_main. do.
Media Contact – Samsung Bioepis
Anna Nayun Kim, nayun86. kim@samsung. comJane Chung, ejane. chung@samsung. com
View content to download media: https://www. prnewswire. com/news-releases/samsung-invests-in-brickbio-to-develop-advanced-molecules-and-therapies-using-protein-engineering-technology-for – anticorps-conjugués-medicamentos-adc-302091366. html
SOURCEBriqueBio